Orchid Pharma informs about outcome of board meeting

08 Feb 2024 Evaluate
Orchid Pharma has informed that pursuant to Regulation 30 read Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) and in reference to the Intimation given on February 02, 2024 of Board Meeting, the Board of Directors of the Company at its meeting held today i.e. February 08, 2024 (commenced at 01.00 pm and concluded at 03.35 pm) has considered and approved the Un-Audited Standalone & Consolidated Financial Result of the Company for quarter ended on December 31, 2023. Copy of Un-Audited Standalone & Consolidated Financial Result along with Limited Review Reports issued by Singhi & Co., a Chartered Accountant Firm, Statutory Auditors of the Company, are enclosed. Further, pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 statement of utilisation and deviation or variation for quarter ended on December 31, 2023 is annexed. These are also being made available on the official website of the Company i.e. http://www.orchidpharma.com/

The above information is a part of company’s filings submitted to BSE.

Orchid Pharma Share Price

1001.05 -0.95 (-0.09%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.